📊 NUMD Key Takeaways
Is Nu-Med Plus, Inc. (NUMD) a Good Investment?
Nu-Med Plus is in severe financial distress with negative stockholders' equity of -$215.1K, indicating the company is technically insolvent. Revenue has collapsed 400% YoY to negative territory while operating losses continue to mount, demonstrating fundamental business failure. The company has minimal cash reserves of $2.4K against $224.5K in liabilities and negative operating cash flow, indicating imminent insolvency without significant capital infusion.
Nu-Med Plus exhibits essentially no revenue, persistent losses, and acute balance-sheet stress with negative equity and minimal cash. Reported margins are distorted by negative revenue, while ROA and interest coverage point to insolvency risk. Without a near-term capital raise and tangible, recurring revenue traction, the fundamentals remain untenable.
Why Buy Nu-Med Plus, Inc. Stock? NUMD Key Strengths
- Minimal capital expenditure requirements reduce cash burn in operations
- Zero long-term debt structure limits refinancing risk
- Severely distressed valuation may offer distressed asset recovery opportunity for turnaround specialists
- Asset-light model with zero capex requirements
- Net loss improved YoY, suggesting some cost control
- No long-term debt recorded, limiting fixed obligations
NUMD Stock Risks: Nu-Med Plus, Inc. Investment Risks
- Negative stockholders' equity indicates technical insolvency and heightened bankruptcy risk
- Revenue collapse of 400% YoY demonstrates total loss of business viability
- Critical liquidity crisis with current ratio of 0.04x and only $2.4K cash against $224.5K liabilities
- Negative operating cash flow of -$4.4K indicates operational losses are not self-sustaining
- Complete absence of profitability with net income loss of $68.3K in latest period
- No insider buying activity in past 90 days suggests management confidence is absent
- Going-concern risk given negative equity, 0.04x current ratio, and minimal cash
- High dilution risk from likely capital raises to fund operations
- Execution risk in returning to positive, sustainable revenue
Key Metrics to Watch
- Stockholders equity trend - any improvement from negative -$215.1K position
- Monthly revenue stabilization - current negative revenue is unsustainable
- Cash burn rate and runway until complete depletion of $2.4K reserves
- Debt covenant compliance and default risk
- Asset liquidation values and going concern assessment
- Cash & Equivalents
- Revenue (return to positive, growth rate)
Nu-Med Plus, Inc. (NUMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 88.7% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. The current ratio below 1.0x warrants monitoring of short-term liquidity.
NUMD Profit Margin, ROE & Profitability Analysis
NUMD vs Healthcare Sector: How Nu-Med Plus, Inc. Compares
How Nu-Med Plus, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nu-Med Plus, Inc. Stock Overvalued? NUMD Valuation Analysis 2026
Based on fundamental analysis, Nu-Med Plus, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nu-Med Plus, Inc. Balance Sheet: NUMD Debt, Cash & Liquidity
NUMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nu-Med Plus, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.00 indicates the company is currently unprofitable.
NUMD Revenue Growth, EPS Growth & YoY Performance
NUMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2021 | N/A | -$153.3K | N/A |
| Q3 2020 | N/A | -$150.6K | N/A |
| Q2 2020 | N/A | -$153.3K | N/A |
| Q1 2020 | N/A | -$153.3K | $0.00 |
| Q3 2019 | N/A | -$147.5K | N/A |
| Q2 2019 | N/A | -$147.5K | N/A |
| Q1 2019 | N/A | -$147.5K | N/A |
| Q3 2018 | N/A | -$143.0K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nu-Med Plus, Inc. Dividends, Buybacks & Capital Allocation
NUMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nu-Med Plus, Inc. (CIK: 0001543637)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NUMD
What is the AI rating for NUMD?
Nu-Med Plus, Inc. (NUMD) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NUMD's key strengths?
Claude: Minimal capital expenditure requirements reduce cash burn in operations. Zero long-term debt structure limits refinancing risk. ChatGPT: Asset-light model with zero capex requirements. Net loss improved YoY, suggesting some cost control.
What are the risks of investing in NUMD?
Claude: Negative stockholders' equity indicates technical insolvency and heightened bankruptcy risk. Revenue collapse of 400% YoY demonstrates total loss of business viability. ChatGPT: Going-concern risk given negative equity, 0.04x current ratio, and minimal cash. High dilution risk from likely capital raises to fund operations.
What is NUMD's revenue and growth?
Nu-Med Plus, Inc. reported revenue of $-5.0K.
Does NUMD pay dividends?
Nu-Med Plus, Inc. does not currently pay dividends.
Where can I find NUMD SEC filings?
Official SEC filings for Nu-Med Plus, Inc. (CIK: 0001543637) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NUMD's EPS?
Nu-Med Plus, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NUMD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Nu-Med Plus, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NUMD stock overvalued or undervalued?
Valuation metrics for NUMD: ROE of N/A (sector avg: 15%), net margin of 1,366.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NUMD stock in 2026?
Our dual AI analysis gives Nu-Med Plus, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is NUMD's free cash flow?
Nu-Med Plus, Inc.'s operating cash flow is $-4.4K, with capital expenditures of $0.0. FCF margin is 88.7%.
How does NUMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 1,366.9% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.04 (avg: 2).